Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maxcyte (MXCT) Operating Leases (2020 - 2026)

Maxcyte has reported Operating Leases over the past 6 years, most recently at $16.5 million for Q4 2025.

  • Quarterly Operating Leases fell 3.98% to $16.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $16.5 million through Dec 2025, down 3.98% year-over-year, with the annual reading at $16.5 million for FY2025, 3.98% down from the prior year.
  • Operating Leases was $16.5 million for Q4 2025 at Maxcyte, down from $16.8 million in the prior quarter.
  • Over five years, Operating Leases peaked at $18.0 million in Q4 2023 and troughed at $500200.0 in Q3 2021.
  • The 5-year median for Operating Leases is $15.9 million (2022), against an average of $14.0 million.
  • Year-over-year, Operating Leases skyrocketed 2873.17% in 2022 and then dropped 4.45% in 2024.
  • A 5-year view of Operating Leases shows it stood at $5.2 million in 2021, then skyrocketed by 209.18% to $15.9 million in 2022, then rose by 12.74% to $18.0 million in 2023, then decreased by 4.45% to $17.2 million in 2024, then decreased by 3.98% to $16.5 million in 2025.
  • Per Business Quant, the three most recent readings for MXCT's Operating Leases are $16.5 million (Q4 2025), $16.8 million (Q3 2025), and $17.2 million (Q2 2025).